Glaucoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mimecan and activinA, which have been shown to be upregulated in models of glaucoma, were both found to be elevated in POAG TM.
|
16565384 |
2006 |
Glaucoma, Primary Open Angle
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Mimecan and activinA, which have been shown to be upregulated in models of glaucoma, were both found to be elevated in POAG TM.
|
16565384 |
2006 |
Neoplasm Metastasis
|
0.310 |
Biomarker
|
phenotype |
CTD_human |
Proteomic analysis identifies candidate proteins associated with distant recurrences in breast cancer after adjuvant chemotherapy.
|
17085005 |
2007 |
Colorectal Carcinoma
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
This study clearly demonstrated that absence of mimecan and upregulation of TXNDC5 are involved in the early development of colorectal cancer.
|
17895523 |
2007 |
Malignant neoplasm of colon and/or rectum
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
This study clearly demonstrated that absence of mimecan and upregulation of TXNDC5 are involved in the early development of colorectal cancer.
|
17895523 |
2007 |
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
All adenoma and cancer tissues did not express mimecan, but all normal mucosa did (P < 0.01).
|
17895523 |
2007 |
Adenoma of large intestine
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Differential expression of mimecan and thioredoxin domain-containing protein 5 in colorectal adenoma and cancer: a proteomic study.
|
17895523 |
2007 |
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
All adenoma and cancer tissues did not express mimecan, but all normal mucosa did (P < 0.01).
|
17895523 |
2007 |
Adenoma
|
0.010 |
AlteredExpression
|
group |
LHGDN |
All adenoma and cancer tissues did not express mimecan, but all normal mucosa did (P < 0.01).
|
17895523 |
2007 |
Aortic Valve Stenosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, these data implicate Ogn as a key regulator of LVM in rats, mice and humans, and suggest that Ogn modifies the hypertrophic response to extrinsic factors such as hypertension and aortic stenosis.
|
18443592 |
2008 |
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Taken together, these data implicate Ogn as a key regulator of LVM in rats, mice and humans, and suggest that Ogn modifies the hypertrophic response to extrinsic factors such as hypertension and aortic stenosis.
|
18443592 |
2008 |
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This is the first study showing that mimecan could serve as an excellent pathological biomarker to distinguish NSCLCs from SCLCs.
|
19787221 |
2009 |
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, we hypothesize that mimecan could serve as a biomarker for differentiating various histological types of lung cancers.
|
19787221 |
2009 |
Cervical Squamous Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A differential protein pattern for SCC was, e.g. over-expressed (OE) eukaryotic translation initiation factor 3-2β, neutrophil cytosolic factor 2, annexin A6 (ANXA6), for SVC it was OE cathepsin D, γ-catenin, RAB2A, for both cancers it was OE apolipoprotein E, tropomyosin 3, HSPA8, and underexpressed cytokeratin 13, osteoglycin.
|
21137014 |
2010 |
Follicular thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Four proteins showed significant differences between FA and FTC (peroxisomal proliferator-activated receptor-γ, serum deprivation response protein, osteoglycin, and dipeptidase 1).
|
23751876 |
2013 |
Neoplasm Metastasis
|
0.310 |
Biomarker
|
phenotype |
BEFREE |
Altogether, our present data first time show that PFN1, NCL, CNDP2 and OGN are novel potential biomarkers for diagnosis and therapeutic targets for laryngeal carcinoma, and PFN1 is involved in the metastasis of laryngeal carcinoma.
|
24587265 |
2014 |
Anorexia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Notably, mimecan-MBP also induced anorexia in A(y)/a and db/db mice.
|
26870797 |
2015 |
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In human heart failure, osteoglycin is a promising biomarker for ischemic heart failure.
|
25520363 |
2015 |
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
In human heart failure, osteoglycin is a promising biomarker for ischemic heart failure.
|
25520363 |
2015 |
Myocardial Infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Adenoviral overexpression of osteoglycin in wild-type mice significantly improved collagen quality, thereby blunting cardiac dilatation and dysfunction after MI.
|
25520363 |
2015 |
Cardiac dilatation
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Adenoviral overexpression of osteoglycin in wild-type mice significantly improved collagen quality, thereby blunting cardiac dilatation and dysfunction after MI.
|
25520363 |
2015 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The present study showed for the first time that higher serum OGN levels were associated with decreased BMD and increased risk of vertebral fractures in postmenopausal women with T2DM.
|
27836731 |
2017 |
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Our findings suggest that LIP deficiency renders tumor cell resistant to ER stress by preventing the induction of Ogn.
|
28383550 |
2017 |
Post-Traumatic Stress Disorder
|
0.030 |
Biomarker
|
disease |
BEFREE |
Twenty-six OEF/OIF combat veterans with PTSD who had recently returned from a combat zone were block randomized to receive eight sessions of MBSR or present-centered group therapy (PCGT).
|
28890702 |
2017 |
Cardiovascular Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Osteoglycin (OGN) has been noted for its implication in cardiovascular disease in recent studies.
|
28069703 |
2017 |